AP3B2
AP-3 complex subunit beta-2
Also known as: AP3B2_HUMAN, NAPTB
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q13367
- Gene
- AP3B2
- Ensembl
- ENSG00000103723
- Chromosome
- 15
- Canonical length
- 1082 aa
- Protein class
- Disease related genes, Human disease related genes, Predicted intracellular proteins
- Subcellular location
- Nucleoplasm,Golgi apparatus,Cytosol
OverviewNCBI Gene
Adaptor protein complex 3 (AP-3 complex) is a heterotrimeric protein complex involved in the formation of clathrin-coated synaptic vesicles. The protein encoded by this gene represents the beta subunit of the neuron-specific AP-3 complex and was first identified as the target antigen in human paraneoplastic neurologic disorders. The encoded subunit binds clathrin and is phosphorylated by a casein kinase-like protein, which mediates synaptic vesicle coat assembly. Defects in this gene are a cause of early-onset epileptic encephalopathy. [provided by RefSeq, Feb 2017]
Canonical amino-acid sequenceUniProt
1082 residues, UniProt reviewed canonical sequence.
>Q13367|AP3B2
1 MSAAPAYSED KGGSAGPGEP EYGHDPASGG IFSSDYKRHD DLKEMLDTNK DSLKLEAMKR
61 IVAMIARGKN ASDLFPAVVK NVACKNIEVK KLVYVYLVRY AEEQQDLALL SISTFQRGLK
121 DPNQLIRASA LRVLSSIRVP IIVPIMMLAI KEAASDMSPY VRKTAAHAIP KLYSLDSDQK
181 DQLIEVIEKL LADKTTLVAG SVVMAFEEVC PERIDLIHKN YRKLCNLLID VEEWGQVVII
241 SMLTRYARTQ FLSPTQNESL LEENAEKAFY GSEEDEAKGA GSEETAAAAA PSRKPYVMDP
301 DHRLLLRNTK PLLQSRSAAV VMAVAQLYFH LAPKAEVGVI AKALVRLLRS HSEVQYVVLQ
361 NVATMSIKRR GMFEPYLKSF YIRSTDPTQI KILKLEVLTN LANETNIPTV LREFQTYIRS
421 MDKDFVAATI QAIGRCATNI GRVRDTCLNG LVQLLSNRDE LVVAESVVVI KKLLQMQPAQ
481 HGEIIKHLAK LTDNIQVPMA RASILWLIGE YCEHVPRIAP DVLRKMAKSF TAEEDIVKLQ
541 VINLAAKLYL TNSKQTKLLT QYVLSLAKYD QNYDIRDRAR FTRQLIVPSE QGGALSRHAK
601 KLFLAPKPAP VLESSFKDRD HFQLGSLSHL LNAKATGYQE LPDWPEEAPD PSVRNVEVPE
661 WTKCSNREKR KEKEKPFYSD SEGESGPTES ADSDPESESE SDSKSSSESG SGESSSESDN
721 EDQDEDEEKG RGSESEQSEE DGKRKTKKKV PERKGEASSS DEGSDSSSSS SESEMTSESE
781 EEQLEPASWS RKTPPSSKSA PATKEISLLD LEDFTPPSVQ PVSPPAIVST SLAADLEGLT
841 LTDSTLVPSL LSPVSGVGRQ ELLHRVAGEG LAVDYTFSRQ PFSGDPHMVS VHIHFSNSSD
901 TPIKGLHVGT PKLPAGISIQ EFPEIESLAP GESATAVMGI NFCDSTQAAN FQLCTQTRQF
961 YVSIQPPVGE LMAPVFMSEN EFKKEQGKLM GMNEITEKLM LPDTCRSDHI VVQKVTATAN
1021 LGRVPCGTSD EYRFAGRTLT GGSLVLLTLD ARPAGAAQLT VNSEKMVIGT MLVKDVIQAL
1081 TQLocalizationUniProt · AlphaFold · HPA
Whether an antibody against AP3B2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.36
- Highest tissue expression
- 46 nTPM
Expression across tissuesHPA
Tissue
- cerebellum: 46 nTPM
- cerebral cortex: 40 nTPM
- retina: 31 nTPM
- pituitary gland: 30 nTPM
- hypothalamus: 26 nTPM
- hippocampal formation: 25 nTPM
Single-cell type
- rod photoreceptor cells: 306 nCPM
- gonadotrophs: 156 nCPM
- lactotrophs: 128 nCPM
- cone photoreceptor cells: 116 nCPM
- thyrotrophs: 106 nCPM
- retinal bipolar cells: 104 nCPM
Immune cell
- neutrophil: 0.7 nTPM
- plasmacytoid DC: 0.4 nTPM
- memory CD8 T-cell: 0.3 nTPM
- naive CD4 T-cell: 0.3 nTPM
- naive CD8 T-cell: 0.2 nTPM
- basophil: 0.1 nTPM
Brain region
- hippocampal formation: 89 nTPM
- cerebral cortex: 87 nTPM
- basal ganglia: 86 nTPM
- pons: 81 nTPM
- cerebellum: 79 nTPM
- amygdala: 77 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about AP3B2.
Disease | AllUniProt
Conditions AP3B2 is implicated in, by any mechanism.
- Developmental and epileptic encephalopathy 48 (DEE48) MIM:617276
Disease | GeneticClinVar
51 pathogenic / likely-pathogenic of 941 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Developmental and epileptic encephalopathy, 48
- Epileptic encephalopathy
ReferencesPubMed · IEDB
Publications for AP3B2 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
3 publications
- Cerebellar ataxia and myeloradiculopathy associated with AP3B2 antibody: a case report and literature review.
2021 · J Neurol · RCR 0.8 · 10 citations - Mild Cognitive Impairment in Chronic Brain Injury Associated with Serum Anti-AP3B2 Autoantibodies: Report and Literature Review.
2021 · Brain Sci · RCR 0.5 · 7 citations - Case Report: Subacute combined degeneration of the spinal cord mimic accompanying adaptor protein-3B2-IgG.
2025 · Front Immunol
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.34
- gnomAD pLI
- 0.77
- gnomAD missense Z
- 2.92
- DepMap mean gene effect
- -0.02
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- anterograde axonal transport
- anterograde synaptic vesicle transport
- clathrin-coated vesicle cargo loading, AP-3-mediated
- intracellular protein transport
- synaptic vesicle coating
- synaptic vesicle recycling
- vesicle-mediated transport
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Clathrin/coatomer adaptor, adaptin-like, N-terminal
- Armadillo-like helical
- Clathrin adaptor, appendage, Ig-like subdomain superfamily
- Armadillo-type fold
- AP complex subunit beta
- AP-3 complex subunit beta
- AP-3 complex subunit beta, C-terminal domain
- AP-3 complex subunit beta-1/2, C-terminal domain
- Adaptin N terminal region
- Clathrin-adaptor complex-3 beta-1 subunit C-terminal
- AP-3 complex subunit beta-1, C-terminal domain
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of AP3B2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads AP3B2 as an antibody target. Whether an autoantibody or antibody against AP3B2 could matter depends on whether native AP3B2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
AP3B2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label AP3B2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...